Long‑term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor‑resistant gastroesophageal reflux disease

Shinozaki,Satoshi; Osawa,Hiroyuki; Hayashi,Yoshikazu; Miura,Yoshimasa; Lefor,Alan Kawarai; Yamamoto,Hironori

doi:10.3892/br.2021.1408

Long‑term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor‑resistant gastroesophageal reflux disease

Authors:
- Satoshi Shinozaki
- Hiroyuki Osawa
- Yoshikazu Hayashi
- Yoshimasa Miura
- Alan Kawarai Lefor
- Hironori Yamamoto
View Affiliations

Affiliations: Shinozaki Medical Clinic, Utsunomiya, Tochigi 321‑3223, Japan, Department of Medicine, Division of Gastroenterology, Jichi Medical University, Shimotsuke, Tochigi 329‑0498, Japan, Department of Surgery, Jichi Medical University, Shimotsuke, Tochigi 329‑0498, Japan
Published online on: February 1, 2021 https://doi.org/10.3892/br.2021.1408
Article Number: 32

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vonoprazan, a novel potassium‑competitive acid blocker, results in greater inhibition of gastric acid secretion than proton pump inhibitors (PPI). The aim of this study was to assess the long‑term outcomes of patients with PPI‑resistant gastroesophageal reflux disease (GERD) treated with vonoprazan. The medical records of patients with symptomatic GERD treated with vonoprazan for 1 year were retrospectively reviewed. Changes in abdominal symptoms were assessed using the Izumo scale, a self‑reported questionnaire which is useful in evaluating the symptoms of GERD, epigastric pain, postprandial distress, constipation and diarrhea, and is commonly used in routine clinical practice. A total of 30 patients were included and stratified into a non‑erosive (n=22) and erosive group (n=8). At baseline, postprandial distress symptoms were significantly greater in the non‑erosive group compared with the erosive group (P=0.013). Even with vonoprazan therapy, symptoms of GERD in the non‑erosive group were refractory compared with the erosive group, and required additional treatment in a larger proportion of patients (45 vs. 13%). GERD symptoms in the non‑erosive group significantly improved from baseline and remained better after 1 year of vonoprazan therapy, similar to the erosive group. In addition, vonoprazan improved epigastric pain and postprandial distress symptoms in the non‑erosive group, and 1 year of vonoprazan therapy did not aggravate constipation or diarrhea. In conclusion, 1 year of vonoprazan therapy improves GERD symptoms in patients with PPI‑resistant GERD.

View Figures

View References

1	Iwakiri K, Kinoshita Y, Habu Y, Oshima T, Manabe N, Fujiwara Y, Nagahara A, Kawamura O, Iwakiri R, Ozawa S, et al: Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 51:751–767. 2016.PubMed/NCBI View Article : Google Scholar
2	El-Serag H, Becher A and Jones R: Systematic review: Persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther. 32:720–737. 2010.PubMed/NCBI View Article : Google Scholar
3	Frazzoni M, Conigliaro R and Melotti G: Weakly acidic refluxes have a major role in the pathogenesis of proton pump inhibitor-resistant reflux oesophagitis. Aliment Pharmacol Ther. 33:601–606. 2011.PubMed/NCBI View Article : Google Scholar
4	Iwakiri K, Sano H, Tanaka Y, Kawami N, Umezawa M, Futagami S, Hoshihara Y, Nomura T, Miyashita M and Sakamoto C: Characteristics of symptomatic reflux episodes in patients with non-erosive reflux disease who have a positive symptom index on proton pump inhibitor therapy. Digestion. 82:156–161. 2010.PubMed/NCBI View Article : Google Scholar
5	Kagami T, Sahara S, Ichikawa H, Uotani T, Yamade M, Sugimoto M, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, et al: Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther. 43:1048–1059. 2016.PubMed/NCBI View Article : Google Scholar
6	Mori H and Suzuki H: Role of acid suppression in acid-related diseases: proton pump inhibitor and potassium-competitive acid blocker. J Neurogastroenterol Motil. 25:6–14. 2019.PubMed/NCBI View Article : Google Scholar
7	Shinozaki S, Kobayashi Y, Osawa H, Sakamoto H, Hayashi Y, Lefor AK and Yamamoto H: Effectiveness and safety of vonoprazan versus proton pump inhibitors for second-line Helicobacter pylori eradication therapy: systematic review and meta-analysis. Digestion. 1–7. 2020.PubMed/NCBI View Article : Google Scholar
8	Shinozaki S, Osawa H, Hayashi Y, Sakamoto H, Kobayashi Y, Lefor AK and Yamamoto H: Vonoprazan 10 mg daily is effective for the treatment of patients with proton pump inhibitor-resistant gastroesophageal reflux disease. Biomed Rep. 7:231–235. 2017.PubMed/NCBI View Article : Google Scholar
9	Iwakiri K, Sakurai Y, Shiino M, Okamoto H, Kudou K, Nishimura A, Hiramatsu N, Umegaki E and Ashida K: A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis. Therap Adv Gastroenterol. 10:439–451. 2017.PubMed/NCBI View Article : Google Scholar
10	Yamashita H, Kanamori A, Kano C, Hashimura H, Matsumoto K, Tsujimae M, Yoshizaki T, Momose K, Obata D, Eguchi T, et al: The Effects of switching to vonoprazan, a novel potassium-competitive acid blocker, on gastric acidity and reflux patterns in patients with erosive esophagitis refractory to proton pump inhibitors. Digestion. 96:52–59. 2017.PubMed/NCBI View Article : Google Scholar
11	Okuyama M, Nakahara K, Iwakura N, Hasegawa T, Oyama M, Inoue A, Ishizu H, Satoh H and Fujiwara Y: Factors associated with potassium-competitive acid blocker non-response in patients with proton pump inhibitor-refractory gastroesophageal reflux disease. Digestion. 95:281–287. 2017.PubMed/NCBI View Article : Google Scholar
12	Hoshino S, Kawami N, Takenouchi N, Umezawa M, Hanada Y, Hoshikawa Y, Kawagoe T, Sano H, Hoshihara Y, Nomura T, et al: Efficacy of vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Digestion. 95:156–161. 2017.PubMed/NCBI View Article : Google Scholar
13	Kakuta E, Yamashita N, Katsube T, Kushiyama Y, Suetsugu H, Furuta K and Kinoshita Y: Abdominal symptom-related QOL in individuals visiting an outpatient clinic and those attending an annual health check. Intern Med. 50:1517–1522. 2011.PubMed/NCBI View Article : Google Scholar
14	Shinozaki S, Osawa H, Kobayashi Y, Sakamoto H, Hayashi Y, Miura Y, Kawarai Lefor A and Yamamoto H: Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan. Scand J Gastroenterol. 53:897–904. 2018.PubMed/NCBI View Article : Google Scholar
15	Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, et al: Endoscopic assessment of oesophagitis: Clinical and functional correlates and further validation of the Los Angeles classification. Gut. 45:172–180. 1999.PubMed/NCBI View Article : Google Scholar
16	Kimura K and Takemoto T: An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1:87–97. 1969.
17	Furuta K, Ishihara S, Sato S, Miyake T, Ishimura N, Koshino K, Tobita H, Moriyama I, Amano Y, Adachi K, et al: Development and verification of the Izumo Scale, new questionnaire for quality of life assessment of patients with gastrointestinal symptoms. Nihon Shokakibyo Gakkai Zasshi. 106:1478–1487. 2009.PubMed/NCBI(In Japanese).
18	Fujishiro M, Kushiyama A, Yamazaki H, Kaneko S, Koketsu Y, Yamamotoya T, Kikuchi T, Sakoda H, Suzuki R and Kadowaki T: Gastrointestinal symptom prevalence depends on disease duration and gastrointestinal region in type 2 diabetes mellitus. World J Gastroenterol. 23:6694–6704. 2017.PubMed/NCBI View Article : Google Scholar
19	Kinoshita Y and Chiba T: FUTURE Study Group. Characteristics of Japanese patients with chronic gastritis and comparison with functional dyspepsia defined by ROME III criteria: Based on the large-scale survey, FUTURE study. Intern Med. 50:2269–2276. 2011.PubMed/NCBI View Article : Google Scholar
20	Okimoto E, Ishimura N, Morito Y, Mikami H, Shimura S, Uno G, Tamagawa Y, Aimi M, Oshima N, Kawashima K, et al: Prevalence of gastroesophageal reflux disease in children, adults, and elderly in the same community. J Gastroenterol Hepatol. 30:1140–1146. 2015.PubMed/NCBI View Article : Google Scholar
21	Shinozaki S, Osawa H, Sakamoto H, Hayashi Y, Kawarai Lefor A and Yamamoto H: The effect of acotiamide on epigastric pain syndrome and postprandial distress syndrome in patients with functional dyspepsia. J Med Invest. 63:230–235. 2016.PubMed/NCBI View Article : Google Scholar
22	Tanabe T, Hoshino S, Kawami N, Hoshikawa Y, Hanada Y, Takenouchi N, Goto O, Kaise M and Iwakiri K: Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Esophagus. 16:377–381. 2019.PubMed/NCBI View Article : Google Scholar
23	Fass R and Sifrim D: Management of heartburn not responding to proton pump inhibitors. Gut. 58:295–309. 2009.PubMed/NCBI View Article : Google Scholar
24	Hershcovici T, Jha LK, Cui H, Powers J and Fass R: Night-time intra-oesophageal bile and acid: A comparison between gastro-oesophageal reflux disease patients who failed and those who were treated successfully with a proton pump inhibitor. Aliment Pharmacol Ther. 33:837–844. 2011.PubMed/NCBI View Article : Google Scholar
25	Masaoka T, Kameyama H, Yamane T, Yamamoto Y, Takeuchi H, Suzuki H, Kitagawa Y and Kanai T: Pathophysiology of potassium-competitive acid blocker-refractory gastroesophageal reflux and the potential of potassium-competitive acid blocker test. J Neurogastroenterol Motil. 24:577–583. 2018.PubMed/NCBI View Article : Google Scholar
26	Pinto-Sanchez MI, Yuan Y, Hassan A, Bercik P and Moayyedi P: Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev. 11(CD011194)2017.PubMed/NCBI View Article : Google Scholar
27	Miwa H, Nakajima K, Yamaguchi K, Fujimoto K, Veldhuyzen VAN, Zanten SJ, Kinoshita Y, Adachi K, Kusunoki H and Haruma K: Generation of dyspeptic symptoms by direct acid infusion into the stomach of healthy Japanese subjects. Aliment Pharmacol Ther. 26:257–264. 2007.PubMed/NCBI View Article : Google Scholar
28	Ishii M, Manabe N, Kusunoki H, Kamada T, Sato M, Imamura H, Shiotani A, Hata J and Haruma K: Real-time evaluation of dyspeptic symptoms and gastric motility induced by duodenal acidification using noninvasive transnasal endoscopy. J Gastroenterol. 43:935–941. 2008.PubMed/NCBI View Article : Google Scholar
29	Ichikawa H, Sugimoto M, Sugimoto K, Andoh A and Furuta T: Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis. J Gastroenterol Hepatol. 31:716–726. 2016.PubMed/NCBI View Article : Google Scholar
30	Takeuchi T, Furuta T, Fujiwara Y, Sugimoto M, Kasugai K, Kusano M, Okada H, Suzuki T, Higuchi T, Kagami T, et al: Randomised trial of acid inhibition by vonoprazan 10/20 mg once daily vs rabeprazole 10/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study). Aliment Pharmacol Ther. 51:534–543. 2020.PubMed/NCBI View Article : Google Scholar
31	Sakurai Y, Mori Y, Okamoto H, Nishimura A, Komura E, Araki T and Shiramoto M: Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects - a randomised open-label cross-over study. Aliment Pharmacol Ther. 42:719–730. 2015.PubMed/NCBI View Article : Google Scholar
32	Kinoshita Y, Sakurai Y, Takabayashi N, Kudou K, Araki T, Miyagi T, Iwakiri K and Ashida K: Efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a randomized, placebo-controlled, phase 3 study. Clin Transl Gastroenterol. 10(e00101)2019.PubMed/NCBI View Article : Google Scholar
33	Sugimoto M, Ban H, Hira D, Kamiya T, Otsuka T, Inatomi O, Bamba S, Terada T and Andoh A: Letter: CYP3A4/5 genotype status and outcome of vonoprazan-containing Helicobacter pylori eradication therapy in Japan. Aliment Pharmacol Ther. 45:1009–1010. 2017.PubMed/NCBI View Article : Google Scholar